Domestic Ban on Sale of Celebrex Suggested by Pharmacist Group
Published: 2004-12-23 07:00:00
Updated: 2004-12-23 07:00:00
In an official statement released on December 21st, the Korean Pharmacists for Democratic Society (KPDS) strongly suggested that Pfizer should withdraw Celebrex, a Cox-2 inhibitor for treatment of pain and inflammation, from the domestic market.
The statement is reflective of the recent announ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
